沙美特罗丙酸氟替卡松吸入治疗对稳定期慢性阻塞性肺疾病患者的临床疗效和肺功能影响

目的研究沙美特罗丙酸氟替卡松吸入治疗对稳定期慢性阻塞性肺疾病（COPD）患者的临床疗效和肺功能影响.方法选取 2013 年 12 月～ 2015 年8 月我院收治的稳定期COPD患者108例,将其随机分为对照组和试验组,每组各54例.对照组采取常规基础治疗,试验组在对照组治疗上加用沙美特罗丙酸氟替卡松吸入治疗.经过3个月规律治疗,对比试验组和对照组两组的临床疗效、生活质量以及肺功能的改善情况,记录药物相关不良反应.结果通过 3 个月的规律治疗 , 治疗组总有效率 75.93% 高于对照组55.56%, 差异具有统计学意义 （χ2=4.97,P〈0.05）.两组患者生活质量、运动耐量、肺功能情况和动脉血气分析情况与各自治疗前相比均较有改善：SGRQ各能区分值和总分分值均降低,6MWT值上升,FEV1、FEV1占预计值和FEV1 /FVC 升高,PaCO2均降低,PaO2 均升高,差异具有显著性（P 〈0.05）.治疗后两组生活质量、运动耐量、肺功能以及动脉血气分析情况相比较 , 试验组改善情况优于对照组,两者相比差异有统计学意义（P 〈0.05）.结论应用沙美特罗丙酸氟替卡松吸入治疗稳定期COPD具有较好的疗效,可有效恢复患者肺功能,对改善患者生活质量有重大意义,不良反应少,值得临床推广.

ObjectiveTo study salmeterol propionic acid fluoride fluticasone propionate inhalation therapy on stable chronic obstructive pulmonary disease （COPD） patients with the clinical efficacy and effect on lung function. Methods108 patients with stable COPD in our hospital from December 2013 to August 2015 were randomly divided into the control group and the experimental group, 54 cases in each group. The control group take routine treatment, the experimental group in the control group were treated with fluticasone propionate inhalation in the treatment of Shah Mette Lo.After 3 months of treatment, the clinical efficacy, quality of life and improvement of lung function in the two groups were compared with the experimental group and the control group. Resultsthrough 3 months of regular treatment, the treatment group the total efficiency was 75.93% higher than that of the control group was 55.56%, the difference is statistically significant （X2 2=4.97, P 〈 0.05）. Two groups of patients quality of life, exercise tolerance, lung function and arterial blood gas analysis and their respective treatment than before to have improved SGRQ the district scores and total scores were lower, 6MWT value increased, FEV1, FEV1 percentage of predicted value and FEV1 / FVC increased, PaCO2 decreased, PaO2 increased, the difference is significant （P 〈 0.05）. After treatment, the quality of life, exercise tolerance, pulmonary function and arterial blood gas analysis were compared between the two groups. The improvement of the experimental group was better than that of the control group, and the difference was statistically significant （P〈0.05 ）. Conclusionsalmeterol propionic acid fluoride fluticasone propionate inhalation therapy has better curative effects on patients with stable COPD and can effectively restore the lung function of patients and to improve the quality of life of patients with a significant, with less adverse reactions worthy of clinical promotion.